Saturday 17 October 2026
Export SHPH’s income statement to Excel — free account
Shuttle Pharmaceuticals Holdings, Inc.
SHPH Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, EPS grew 90.6% and free cash flow grew 82.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
5.08
0.49
−8.80%
Follow SHPH
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | 2,700.00 | 834.00 | 145.00 | 12.60 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | 252,520.00 | 5,740.00 | 1,236.00 | 252.50 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | 5 | 7 | 8 | 9 | 2 | ||||
| Revenue/emp, $m | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — | — | — | |||||
| EBT | — | 0 | (1) | — | (1) | (1) | (5) | (7) | (9) | (12) | |||||
| EBT margin, % | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | (1) | — | (1) | (1) | (5) | (7) | (9) | (12) | |||||
| Depreciation | — | 0 | 0 | — | 0 | 0 | 0 | 2 | 1 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | (0.02) | (0.05) | — | (0.07) | (247.72) | (580.00) | (880.00) | (797.50) | (71.60) | |||||
| Cash flow | — | (0.01) | (0.04) | — | 0.00 | (63.89) | (493.78) | (744.15) | (637.15) | (57.89) | |||||
| Capex | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | (2.53) | 0.00 | (18.66) | |||||
| Free cash flow | — | (0.01) | (0.04) | — | 0.00 | (63.89) | (493.78) | (746.68) | (637.15) | (76.55) | |||||
| Book value | — | (0.02) | 0.00 | — | (0.12) | (346.40) | 1,421.83 | 540.77 | 61.67 | 13.76 | |||||
| Shares, m | — | 14 | 14 | — | 14 | 0 | 0 | 0 | 0 | 0 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | 0 | (1) | — | 0 | 0 | (3) | (6) | (7) | (9) | ||||
| Capex | — | — | — | — | 0 | — | — | 0 | — | (3) | |||||
| Free cash flow | — | 0 | (1) | — | 0 | 0 | (3) | (6) | (7) | (13) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | 0 | 0 | — | (2) | (2) | 8 | 5 | 1 | (7) | ||||
| Total debt | — | 0 | 0 | — | 1 | 0 | 1 | 0 | — | — | |||||
| Net debt | — | 0 | 0 | — | 1 | 0 | (8) | (5) | (2) | 0 | |||||
| Shareholders’ equity | — | 0 | 0 | — | (2) | (2) | 8 | 4 | 1 | 2 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | 0.00 | (168.62) | — | (155.98) | (209.97) | (145.02) | (90.28) | (216.24) | (180.58) | ||||
| ROIC | — | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (387.84) | |||||
| ROE | — | 0.00 | 487.62 | — | 109.31 | 75.65 | (223.05) | (112.37) | (383.83) | (791.04) | |||||
Negative figures in brackets.
Fundamentals updated 2 Oct 2026
Charts ten years each
Shuttle Pharmaceuticals Holdings, Inc. vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ZYBT Zhengye Biotechnology Holding Limited | $44.6M | — | — | — | — | −69.31% (below 0%: shrinking) | — | — | Compare |
| SCYX SCYNEXIS, Inc. | $38.9M | — (loss-making) | — (loss-making) | −8.56% (below 0%: shrinking) | n/m | −98.60% (below 0%: shrinking) | 100.00% | (3,308.51%) | Compare |
| IXHL Incannex Healthcare Inc. | $36.1M | — (loss-making) | — (loss-making) | −92.31% (below 0%: shrinking) | n/m | +327.73% (above 0%: growing) | 100.00% | 0.00% | Compare |
| RMTI Rockwell Medical, Inc. | $32.2M | — (loss-making) | — (loss-making) | +10.63% (above 0%: growing) | n/m | −12.92% (below 0%: shrinking) | 18.24% | (5.97%) | Compare |
| CPHI China Pharma Holdings, Inc. | $31.3M | — (loss-making) | — (loss-making) | −7.56% (below 0%: shrinking) | n/m | −113.57% (below 0%: shrinking) | 8.82% | (150.99%) | Compare |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. | $26.5M | 0.2× | — | — | n/m | +82.01% (above 0%: growing) | 0.00% | 0.00% | |
| TXMD TherapeuticsMD, Inc. | $22.3M | — (loss-making) | 18.9× | −8.72% (below 0%: shrinking) | −80.00% (below 0%: shrinking) | +104.46% (above 0%: growing) | 100.00% | (93.90%) | Compare |
| AYTU Aytu BioPharma, Inc. | $21.8M | — (loss-making) | — (loss-making) | +6.42% (above 0%: growing) | n/m | +57.72% (above 0%: growing) | 64.63% | (4.82%) | Compare |
| UPC Universe Pharmaceuticals INC | $20.9M | — (loss-making) | 4.1× | −23.98% (below 0%: shrinking) | −110.15% (below 0%: shrinking) | −84.99% (below 0%: shrinking) | 32.57% | 0.00% | Compare |
| Median of peers | $31.7M | — | — | −8.56% | — | −41.11% | 64.63% | (5.97%) |
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) key facts
- Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, SHPH traded at $5.08, a market capitalization of $26.5 million.
- Return on equity was −791.0% and debt-to-equity 0.00.